Rafael Holdings CEO Conkling Steps Down; Replaced by Former CEO Jonas

Dow Jones

04/25

By Roshan Fernandez

Rafael Holdings said Chief Executive Bill Conkling will be stepping down from his role following the clinical and early-stage pharmaceutical company's merger with Cyclo Therapeutics.

Conkling's departure is effective May 31. Rafael's executive chairman and former CEO, Howard Jonas, will assume the role of CEO at the Newark, N.J.-based company, effective June 1.

Conkling, who has been CEO since 2022, helped identify opportunities with the potential to transform Rafael into a late-stage clinical biotechnology company. Rafael completed its merger with Cyclo on March 26.

Jonas, 68 years old, has served as chairman of the board since 2017. He was also previously CEO from March 2018 through April 2021.

Write to Roshan Fernandez at roshan.fernandez@wsj.com

(END) Dow Jones Newswires

April 24, 2025 17:33 ET (21:33 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2530399113"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2530399113\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2530399113?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-25 05:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2530399113","market":"other","top_or_hot":-1,"title":"Rafael Holdings CEO Conkling Steps Down; Replaced by Former CEO Jonas","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Roshan Fernandez \n</p>\n<pre>\n \n</pre>\n<p>\n  Rafael Holdings said Chief Executive Bill Conkling will be stepping down from his role following the clinical and early-stage pharmaceutical company's merger with <a href=\"https://laohu8.com/S/CYTH\">Cyclo Therapeutics</a>. \n</p>\n<p>\n  Conkling's departure is effective May 31. Rafael's executive chairman and former CEO, Howard Jonas, will assume the role of CEO at the Newark, N.J.-based company, effective June 1. \n</p>\n<p>\n  Conkling, who has been CEO since 2022, helped identify opportunities with the potential to transform Rafael into a late-stage clinical biotechnology company. Rafael completed its merger with Cyclo on March 26. \n</p>\n<p>\n  Jonas, 68 years old, has served as chairman of the board since 2017. He was also previously CEO from March 2018 through April 2021. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Roshan Fernandez at roshan.fernandez@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 24, 2025 17:33 ET (21:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings CEO Conkling Steps Down; Replaced by Former CEO Jonas</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings CEO Conkling Steps Down; Replaced by Former CEO Jonas\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-04-25 05:33</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Roshan Fernandez \n</p>\n<pre>\n \n</pre>\n<p>\n  Rafael Holdings said Chief Executive Bill Conkling will be stepping down from his role following the clinical and early-stage pharmaceutical company's merger with <a href=\"https://laohu8.com/S/CYTH\">Cyclo Therapeutics</a>. \n</p>\n<p>\n  Conkling's departure is effective May 31. Rafael's executive chairman and former CEO, Howard Jonas, will assume the role of CEO at the Newark, N.J.-based company, effective June 1. \n</p>\n<p>\n  Conkling, who has been CEO since 2022, helped identify opportunities with the potential to transform Rafael into a late-stage clinical biotechnology company. Rafael completed its merger with Cyclo on March 26. \n</p>\n<p>\n  Jonas, 68 years old, has served as chairman of the board since 2017. He was also previously CEO from March 2018 through April 2021. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Roshan Fernandez at roshan.fernandez@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 24, 2025 17:33 ET (21:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RFL","symbol_name":"Rafael Holdings, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2530399113","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2530399113","pubTimestamp":1745530380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Rafael Holdings said Chief Executive Bill Conkling will be stepping down from his role following the clinical and early-stage pharmaceutical company's merger with Cyclo Therapeutics.Conkling's departure is effective May 31. Rafael's executive chairman and former CEO, Howard Jonas, will assume the role of CEO at the Newark, N.J.-based company, effective June 1.Conkling, who has been CEO since 2022, helped identify opportunities with the potential to transform Rafael into a late-stage clinical biotechnology company. Rafael completed its merger with Cyclo on March 26.Jonas, 68 years old, has served as chairman of the board since 2017. He was also previously CEO from March 2018 through April 2021.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"translate_title":"拉斐尔控股CEO康克林卸任；由前首席执行官乔纳斯接替","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RFL":0.9},"content_text":"By Roshan Fernandez \n\n\n \n\n\n  Rafael Holdings said Chief Executive Bill Conkling will be stepping down from his role following the clinical and early-stage pharmaceutical company's merger with Cyclo Therapeutics. \n\n\n  Conkling's departure is effective May 31. Rafael's executive chairman and former CEO, Howard Jonas, will assume the role of CEO at the Newark, N.J.-based company, effective June 1. \n\n\n  Conkling, who has been CEO since 2022, helped identify opportunities with the potential to transform Rafael into a late-stage clinical biotechnology company. Rafael completed its merger with Cyclo on March 26. \n\n\n  Jonas, 68 years old, has served as chairman of the board since 2017. He was also previously CEO from March 2018 through April 2021. \n\n\n \n\n\n  Write to Roshan Fernandez at roshan.fernandez@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 24, 2025 17:33 ET (21:33 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}